Trials / Recruiting
RecruitingNCT06481826
Glofitamab in Chinese Patients With R/R DLBCL
A Study to Evaluate Glofitamab as Single Agent in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glofitamab | Glofitamab given in standard dosage |
Timeline
- Start date
- 2024-01-01
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
- First posted
- 2024-07-01
- Last updated
- 2026-03-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06481826. Inclusion in this directory is not an endorsement.